Editorial
|
|
|
|
|
Unscrupulous pursuit of gain
|
|
|
|
Marketing Authorisations
|
|
|
|
|
First, do no harm
|
|
|
|
|
|
|
|
|
|
No place in either first- or second-line treatment of metastasic colorectal cancer
|
|
|
|
|
|
|
|
|
|
To be avoided, like other DPP-4 inhibitors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Just another fluorouracil percursor
|
|
|
|
Adverse Effects
|
|
|
|
|
Avoid unecessary exposure to latex
|
|
|
|
|
|
|
|
|
|
To be weighed in the harm-benefit balance
|
|
|
|
|
|
|
|
|
|
Packaging must be improved
|
|
|
|
|
|
|
|
|
|
A case reported to Prescrire's Preventing the Preventable programme
|
|
|
|
|
|
|
|
|
|
Do not use this muscle relaxant
|
|
|
|
|
|
|
|
|
|
Sometimes without malignant syndrome
|
|
|
|
|
|
|
|
|
|
|
|
Vitamin K antagonists first
|
|
|
|
Reviews
|
|
|
|
|
Prevention of recurrences
|
|
|
|
|
|
|
|
|
|
Choosing a treatment for deep venous thrombosis and pulmonary embolism
|
|
|
|
|
|
|
|
|
|
Unfavourable harm-benefit balance
|
|
|
|
Outlook
|
|
|
|
|
Health professionals should report dangerous packaging
|
|
|
|
|
|
|
|
|
|
|
|
To avoid pitfalls and misunderstandings
|
|
|
|
|
|
|
|
|
|
Public health is at stake
|
|
|
|
|
|